Together, these results suggest that MCP width may be a clinically useful biomarker for FXTAS, as it was sensitive to FXTAS onset and progression, but not the FMR1 phenotype more generally. Here, FMR1 is linked to fragile X-associated tremor/ataxia syndrome.